COVID-19 cases are on the rise across the United States, with the newly identified variant JN.1, now predominant in the majority of recent cases.
JN.1 has quickly become the fastest-growing and dominant variant, constituting approximately 44.2% of cases in the U.S., according to the latest data released by the CDC on Friday, December 22. The CDC’s findings suggest that the variant is now responsible for an estimated 39% to 50% of all COVID-19 cases, a notable increase from the previously reported range of 15% to 29%.
The CDC further highlights the regional impact of JN.1, noting its highest prevalence in the Northeastern U.S., particularly in states like New Jersey and New York, where it represents nearly 57% of cases. In the Western region (including Arizona, California, and Nevada), the variant accounts for around 41%, while in the mid-Atlantic states (such as Maryland, Pennsylvania, Virginia, and West Virginia), JN.1 is responsible for approximately 39% of cases. The evolving situation with this variant underscores the ongoing challenges in managing and understanding the dynamics of the COVID-19 pandemic.
The surge of the JN.1 variant coincides with a decline in vaccination rates among Americans for COVID-19, influenza, and respiratory syncytial virus (RSV). The CDC issued a health advisory to medical professionals last week, emphasizing that low vaccination rates against these infectious diseases could result in more severe illness and an additional strain on healthcare capacity in the upcoming weeks.
The CDC’s concern extends to the potential for increased disease severity due to inadequate vaccination coverage. The advisory underscores the importance of addressing the vaccination gap to mitigate the impact on both individual health and the healthcare system’s ability to manage the rising cases of respiratory illnesses. the newly identified variant
As the JN.1 variant becomes more prevalent, the need for vaccination against COVID-19, flu, and other viruses becomes even more critical to curbing the spread of infectious diseases and safeguarding public health.
Of most importance to holiday travelers, JN.1 is likely more transmissible than other variants “or better at evading our immune systems than other circulating variants,” the Centers for Disease Control and Prevention said Friday.